ArticleMedical oncology (Northwood, London, England)2025

Synergy Between second-generation FLT3 inhibitors and the ERK1/2 inhibitor Ulixertinib in FLT3-ITD-mutated acute myeloid leukemia (AML) cells.

Daniel Muteb Muyey et al.PubMed ↗Publisher ↗

No numbers read from the abstract.